Analysts Set Smith & Nephew SNATS, Inc. (NYSE:SNN) Price Target at $36.25

Shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) have been assigned a consensus rating of “Hold” from the five analysts that are currently covering the firm, Marketbeat Ratings reports. Four analysts have rated the stock with a hold rating and one has issued a strong buy rating on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $36.25.

Several equities research analysts have commented on SNN shares. Canaccord Genuity Group boosted their target price on Smith & Nephew SNATS from $34.00 to $35.00 and gave the stock a “hold” rating in a report on Thursday, March 5th. Royal Bank Of Canada lowered Smith & Nephew SNATS from an “outperform” rating to a “sector perform” rating in a research report on Monday, December 15th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research note on Wednesday, January 21st. Finally, Wall Street Zen raised shares of Smith & Nephew SNATS from a “buy” rating to a “strong-buy” rating in a research report on Sunday, March 29th.

Smith & Nephew SNATS Trading Up 0.0%

Shares of SNN opened at $32.15 on Tuesday. Smith & Nephew SNATS has a fifty-two week low of $23.91 and a fifty-two week high of $38.79. The firm’s 50-day simple moving average is $34.20 and its two-hundred day simple moving average is $34.21. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.25 and a current ratio of 2.57.

Smith & Nephew SNATS (NYSE:SNN) last issued its quarterly earnings results on Tuesday, February 17th. The medical equipment provider reported $29.55 EPS for the quarter. The company had revenue of $1.60 billion during the quarter. Sell-side analysts forecast that Smith & Nephew SNATS will post 1.69 EPS for the current year.

Smith & Nephew SNATS Dividend Announcement

The company also recently announced a dividend, which will be paid on Wednesday, May 27th. Stockholders of record on Friday, March 27th will be paid a $0.482 dividend. This represents a dividend yield of 304.0%. The ex-dividend date is Friday, March 27th.

Institutional Investors Weigh In On Smith & Nephew SNATS

Institutional investors and hedge funds have recently made changes to their positions in the company. Royal Bank of Canada raised its stake in shares of Smith & Nephew SNATS by 16.7% in the first quarter. Royal Bank of Canada now owns 340,428 shares of the medical equipment provider’s stock worth $9,657,000 after purchasing an additional 48,784 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Smith & Nephew SNATS by 49.2% during the first quarter. Goldman Sachs Group Inc. now owns 1,771,401 shares of the medical equipment provider’s stock valued at $50,255,000 after buying an additional 583,809 shares during the last quarter. Focus Partners Wealth boosted its position in shares of Smith & Nephew SNATS by 59.8% during the first quarter. Focus Partners Wealth now owns 19,438 shares of the medical equipment provider’s stock valued at $552,000 after buying an additional 7,277 shares during the last quarter. Cetera Investment Advisers increased its holdings in Smith & Nephew SNATS by 5.9% in the 2nd quarter. Cetera Investment Advisers now owns 17,731 shares of the medical equipment provider’s stock worth $543,000 after buying an additional 983 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its position in Smith & Nephew SNATS by 6,663.4% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,210,655 shares of the medical equipment provider’s stock worth $37,082,000 after buying an additional 1,192,755 shares during the last quarter. Institutional investors own 25.64% of the company’s stock.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.